Education
About Us
Working with TipRanks
Follow Us
CG Oncology, Inc. (CGON)
NASDAQ:CGON
CGON Analyst Ratings
Strong Buy
13 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
CGON Stock 12 Month Forecast
Average Price Target
$70.00
▲(60.29% Upside)
| Highest Price Target$90.00 | Average Price Target$70.00 | Lowest Price Target$53.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
J.P. Morgan
―
Buy
―
Reiterated
10/20/25
JonesTrading
$75
Buy
71.74%
Upside
Reiterated
10/16/25
Guggenheim
$90
Buy
106.09%
Upside
Initiated
10/07/25
Goldman Sachs
$40→$56
Buy
28.23%
Upside
Reiterated
09/22/25
LifeSci Capital
$90
Buy
106.09%
Upside
Reiterated
09/20/25
Morgan Stanley
$56→$79
Buy
80.90%
Upside
Reiterated
09/17/25
H.C. Wainwright
$75
Buy
71.74%
Upside
Reiterated
09/15/25
Piper Sandler
$55
Buy
25.94%
Upside
Reiterated
09/10/25
Bank of America Securities
$62
Buy
41.97%
Upside
Reiterated
09/10/25
Cantor Fitzgerald
$75
Buy
71.74%
Upside
Reiterated
09/07/25
RBC Capital
$53
Buy
21.36%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Scotiabank
$23
Hold
-47.33%
Downside
Reiterated
05/14/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
J.P. Morgan
―
Buy
―
Reiterated
10/20/25
JonesTrading
$75
Buy
71.74%
Upside
Reiterated
10/16/25
Guggenheim
$90
Buy
106.09%
Upside
Initiated
10/07/25
Goldman Sachs
$40→$56
Buy
28.23%
Upside
Reiterated
09/22/25
LifeSci Capital
$90
Buy
106.09%
Upside
Reiterated
09/20/25
Morgan Stanley
$56→$79
Buy
80.90%
Upside
Reiterated
09/17/25
H.C. Wainwright
$75
Buy
71.74%
Upside
Reiterated
09/15/25
Piper Sandler
$55
Buy
25.94%
Upside
Reiterated
09/10/25
Bank of America Securities
$62
Buy
41.97%
Upside
Reiterated
09/10/25
Cantor Fitzgerald
$75
Buy
71.74%
Upside
Reiterated
09/07/25
RBC Capital
$53
Buy
21.36%
Upside
Reiterated
08/08/25
TD Cowen
―
Buy
―
Reiterated
08/08/25
Analysts Conflicted on These NA Names: Tempus AI, Inc. Class A (NASDAQ: TEM) and CG Oncology, Inc. (NASDAQ: CGON)We believe CG could report mature 24-month CRR at SUO in December 2025, where the potential mature 24- month CRR range is between 31% and 39%. Management has emphasized how strongly these AUA data have resonated with physicians, which is fueling enrollment into the company's other NMIBC trials. CG The BLA Ensuring A Broad Label Management plans to initiate the BLA submission process for creto in the Q4. Track designations should allow CG to use a rolling submission, similar to what JNJ did with TAR-200. To begin a rolling submission, the FDA requires upfront alignment on when information for each module is expected. While CG has clarity on the maturity of efficacy metrics, the company is conducting studies to streamline administration (2-step vs. 5-step) and validate creto's stability.
Scotiabank
$23
Hold
-47.33%
Downside
Reiterated
05/14/25
Best Analysts Covering CG Oncology, Inc.
1 Month
xxx
Success Rate
4/5 ratings generated profit
Average Return
+12.20%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 80.00% of your transactions generating a profit, with an average return of +12.20% per trade.
3 Months
xxx
Success Rate
4/5 ratings generated profit
Average Return
+24.82%
reiterated a xxx
rating 2 months ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 80.00% of your transactions generating a profit, with an average return of +24.82% per trade.
1 Year
Success Rate
5/5 ratings generated profit
Average Return
+60.88%
reiterated a buy rating last month
Copying Sean Laaman's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +60.88% per trade.
2 Years
xxx
Success Rate
5/5 ratings generated profit
Average Return
+60.88%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +60.88% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
CGON Analyst Recommendation Trends
Rating
Jun 25
Jul 25
Aug 25
Sep 25
Oct 25
Strong Buy
14
11
12
19
19
Buy
4
5
4
7
5
Hold
13
14
15
14
8
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
31
30
31
40
32
Each month's total comprises the sum of three months' worth of ratings.
CGON Financial Forecast
CGON Stock Forecast FAQ
What is CGON’s average 12-month price target, according to analysts?
Based on analyst ratings, CG Oncology, Inc.’s 12-month average price target is 70.00.
What is CGON’s upside potential, based on the analysts’ average price target?
CG Oncology, Inc. has 60.29% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is CGON a Buy, Sell or Hold?
CG Oncology, Inc. has a consensus rating of Strong Buy which is based on 13 buy ratings, 0 hold ratings and 0 sell ratings.
What is CG Oncology, Inc.’s price target?
The average price target for CG Oncology, Inc. is 70.00. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $90.00 ,the lowest forecast is $53.00. The average price target represents 60.29% Increase from the current price of $43.67.
The highest analyst price target is $90.00 ,the lowest forecast is $53.00. The average price target represents 60.29% Increase from the current price of $43.67.
What do analysts say about CG Oncology, Inc.?
CG Oncology, Inc.’s analyst rating consensus is a Strong Buy. This is based on the ratings of 13 Wall Streets Analysts.
How can I buy shares of CGON?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.